NCT00134381

Brief Summary

The purpose of this study is to investigate whether topically applied constituents of green tea \[caffeine or (-)-epigallocatechin gallate; EGCG\] have a protective effect on skin exposed to ultraviolet light (UV).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P25-P50 for phase_2 healthy

Timeline
Completed

Started May 2003

Longer than P75 for phase_2 healthy

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2003

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

August 22, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 24, 2005

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2012

Completed
4.8 years until next milestone

Results Posted

Study results publicly available

September 6, 2017

Completed
Last Updated

September 6, 2017

Status Verified

August 1, 2017

Enrollment Period

9.5 years

First QC Date

August 22, 2005

Results QC Date

April 11, 2017

Last Update Submit

August 3, 2017

Conditions

Keywords

Normal volunteer study

Outcome Measures

Primary Outcomes (5)

  • Change in UVB-Induced Active Caspase-3-Positive Keratinocytes by Green Tea Compounds

    The mean change in number of active caspase-3+ apoptotic keratinocytes between 0- and 48-hour time points was calculated for skin biopsy samples of subjects who had been exposed to UVB on symmetrical right and left test sites which were then randomized to receive active test substance (EGCG or caffeine) or placebo (vehicle) at sequential time points after UVB exposure.

    48 hrs

  • Change in UVB-Induced Apoptotic "Sunburn" Cells by Green Tea Compounds

    The mean change in number of apoptotic "sunburn" cells between 0- and 48-hour time points was calculated for skin biopsy samples of subjects who had been exposed to UVB on symmetrical right and left test sites which were then randomized to receive active test substance (EGCG or caffeine) or placebo (vehicle) at sequential time points after UVB exposure.

    48 hr

  • Effect of Topical Applications of 4-6% Caffeine on UVB-Induced Increases in Apoptotic "Sunburn" Cells

    The percentage of apoptotic "sunburn" cells was identified in the 48-hr time point skin biopsy samples of subjects who had been exposed to UVB on symmetrical right and left test sites which were then randomized to receive 4-6% caffeine in cream vehicle or placebo (cream vehicle) at sequential time points after UVB exposure.

    48 hr

  • Effect of Topical Applications of 4-6% Caffeine on UVB-Induced Increases in Caspase-3-Positive Cells

    The percentage of caspase-3-positive cells was identified in the 48-hr time point skin biopsy samples of subjects who had been exposed to UVB on symmetrical right and left test sites which were then randomized to receive 4-6% caffeine in cream vehicle or placebo (cream vehicle) at sequential time points after UVB exposure.

    48 hr

  • Effect of Topical Applications of 4-6% Caffeine on UVB-Induced Increases in Phospho-p53 (Ser15) Positive Cells

    The percentage of phospho-p53 (Ser15) positive cells was identified in the 48-hr time point skin biopsy samples of subjects who had been exposed to UVB on symmetrical right and left test sites which were then randomized to receive 4-6% caffeine in cream vehicle or placebo (cream vehicle) at sequential time points after UVB exposure.

    48 hr

Secondary Outcomes (2)

  • Effect of Green Tea Compounds on UVB-Induced Erythema

    48 hrs

  • Effect of 4-6% Caffeine on UVB-Induced Erythema

    24 hr

Study Arms (2)

active drug

ACTIVE COMPARATOR

bilateral comparison of green tea constituent

Drug: Green Tea

placebo

PLACEBO COMPARATOR

bilateral comparison of placebo vehicle

Drug: Placebo

Interventions

Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)

active drug

Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)

placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The subjects will be normal adult volunteers who are 18 to 65 years of age.

You may not qualify if:

  • Subjects who drink more than two cups of coffee, tea, or caffeinated soda/beverages per day.
  • Subjects who are unable to get an erythemic response (i.e., a sunburn).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UMDNJ Division of Clinical Pharmacology

New Brunswick, New Jersey, 08901, United States

Location

MeSH Terms

Interventions

Tea

Intervention Hierarchy (Ancestors)

Plant PreparationsBiological ProductsComplex MixturesBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Limitations and Caveats

Early termination leading to small numbers of subjects analyzed

Results Point of Contact

Title
Dr M Magliocco
Organization
UMDNJ-Robert Wood Johnson Medical School

Study Officials

  • Melissa Magliocco, MD

    Rutgers, The State University of New Jersey

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 22, 2005

First Posted

August 24, 2005

Study Start

May 1, 2003

Primary Completion

November 1, 2012

Study Completion

November 1, 2012

Last Updated

September 6, 2017

Results First Posted

September 6, 2017

Record last verified: 2017-08

Locations